X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (26) 26
oncology (26) 26
middle aged (23) 23
female (22) 22
adult (20) 20
aged (20) 20
antineoplastic combined chemotherapy protocols - therapeutic use (16) 16
male (13) 13
treatment outcome (12) 12
13-cis retinoic acid (11) 11
chemotherapy (11) 11
index medicus (11) 11
interleukin-2 (11) 11
therapy (10) 10
13-cis-retinoic acid (9) 9
cancer (9) 9
aged, 80 and over (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
disease-free survival (8) 8
randomized-trial (8) 8
breast cancer (7) 7
cisplatin (7) 7
interleukin-2 - therapeutic use (7) 7
maintenance therapy (7) 7
regulatory t-cells (7) 7
carcinoma (6) 6
combined modality therapy (6) 6
immunotherapy (6) 6
immunotherapy - methods (6) 6
research (6) 6
5-fluorouracil (5) 5
adjuvant chemotherapy (5) 5
capecitabine (5) 5
deoxycytidine - analogs & derivatives (5) 5
docetaxel (5) 5
isotretinoin - therapeutic use (5) 5
killer cells, natural - immunology (5) 5
neoplasm metastasis (5) 5
oncology, experimental (5) 5
paclitaxel (5) 5
phase-ii (5) 5
survival (5) 5
tamoxifen (5) 5
taxoids - administration & dosage (5) 5
tumors (5) 5
antineoplastic agents - therapeutic use (4) 4
breast neoplasms - pathology (4) 4
breast neoplasms - therapy (4) 4
cyclophosphamide (4) 4
deoxycytidine - administration & dosage (4) 4
fluorouracil - administration & dosage (4) 4
fluorouracil - analogs & derivatives (4) 4
high-dose chemotherapy (4) 4
high-dose interleukin-2 (4) 4
ifosfamide (4) 4
ifosfamide - administration & dosage (4) 4
immunology (4) 4
killer cells, natural - drug effects (4) 4
medicine, research & experimental (4) 4
neoplasm staging (4) 4
postmenopausal women (4) 4
survival analysis (4) 4
trial (4) 4
vascular endothelial growth factor (4) 4
adenocarcinoma - drug therapy (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
breast neoplasms - drug therapy (3) 3
cancer therapies (3) 3
carboplatin (3) 3
carboplatin - administration & dosage (3) 3
carcinoma, non-small-cell lung - drug therapy (3) 3
care and treatment (3) 3
cd4-cd8 ratio (3) 3
chemotherapy, adjuvant (3) 3
cisplatin - administration & dosage (3) 3
clinical-trials (3) 3
combination (3) 3
dose-response relationship, drug (3) 3
endothelial growth-factor (3) 3
follow-up studies (3) 3
hematology, oncology and palliative medicine (3) 3
interferon alpha-2a (3) 3
interleukin-2 - administration & dosage (3) 3
isotretinoin - administration & dosage (3) 3
leucovorin (3) 3
lung neoplasms - drug therapy (3) 3
lymphocyte count (3) 3
maintenance immunotherapy (3) 3
metastasis (3) 3
methotrexate (3) 3
multicenter phase-ii (3) 3
neoplasm recurrence, local - drug therapy (3) 3
ovarian neoplasms - drug therapy (3) 3
oxaliplatin (3) 3
patients (3) 3
pharmacology & pharmacy (3) 3
phase-ii trial (3) 3
platinum (3) 3
premenopause (3) 3
prospective studies (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by De Placido, Sabino and Gallo, Ciro and De Laurentiis, Michelino and Bisagni, Giancarlo and Arpino, Grazia and Sarobba, Maria Giuseppa and Riccardi, Ferdinando and Russo, Antonio and Del Mastro, Lucia and Cogoni, Alessio Aligi and Cognetti, Francesco and Gori, Stefania and Foglietta, Jennifer and Frassoldati, Antonio and Amoroso, Domenico and Laudadio, Lucio and Moscetti, Luca and Montemurro, Filippo and Verusio, Claudio and Bernardo, Antonio and Lorusso, Vito and Gravina, Adriano and Moretti, Gabriella and Lauria, Rossella and Lai, Antonella and Mocerino, Carmela and Rizzo, Sergio and Nuzzo, Francesco and Carlini, Paolo and Perrone, Francesco and Accurso, Antonello and Agostara, Biagio and Aieta, Michele and Alabiso, Oscar and Alicicco, Maria Grazia and Amadori, Dino and Amaducci, Laura and Amiconi, Gianna and Antuzzi, Giustino and Ardine, Mara and Ardizzoia, Antonio and Aversa, Caterina and Badalamenti, Giuseppe and Barni, Sandro and Basurto, Carlo and Berardi, Rossana and Bergamasco, Cinzia and Bidoli, Paolo and Bighin, Claudia and Biondi, Edoardo and Bisagni, Giancarlo and Boni, Corrado and Borgonovo, Karen and Botta, Mario and Bravi, Stefano and Bruzzi, Paolo and Buono, Giuseppe and Butera, Alfredo and Caldara, Alessia and Candeloro, Giampiero and Cappelletti, Claudia and Cardalesi, Cinzia and Carfora, Elisabetta and Cariello, Anna and Carrozza, Francesco and Cartenì, Giacomo and Caruso, Michele and Casadei, Virginia and Casanova, Claudia and Castori, Luigi and Cavanna, Luigi and Cavazzini, Giovanna and Cazzaniga, Marina and Chilelli, Mario and Chiodini, Paolo and Chiorrini, Silvia and Ciardiello, Fortunato and Ciccarese, Mariangela and Cinieri, Saverio and Clerico, Mario and Coccaro, Mariarosa and Comande, Mario and Corbo, Claudia and Cortino, Giuseppina and Cusenza, Stefania and Daniele, Gennaro and D'arco, Alfonso Maria and D'auria, Giuliana and Dazzi, Claudio and De Angelis, Carmine and de Braud, Filippo and De Feo, Gianfranco and De Matteis, Andrea and De Tursi, Michele and Di Blasio, Anna and di Lucca, Giuseppe and Di Lullo, Liberato and Di Rella, Francesca and Di Renzo, Gianfranco and Di Stefano, Pia and ... and GIM Investigators
The Lancet Oncology, ISSN 1470-2045, 04/2018, Volume 19, Issue 4, pp. 474 - 485
Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly... 
SYSTEM | THERAPY | EFFICACY | ONCOLOGY | FOLLOW-UP | POSTMENOPAUSAL WOMEN | COMBINATION | AROMATASE INHIBITORS | Breast cancer | Product development | Tamoxifen | Analysis
Journal Article
Journal Article
Journal Article
Anticancer Research, ISSN 0250-7005, 12/2015, Volume 35, Issue 12, pp. 6847 - 6853
Background: Premenopausal patients with breast cancer and more than 10 positive axillary nodes (BC>10) have a poor prognosis: In these patients the best... 
Journal Article
Cancer, ISSN 0008-543X, 02/2006, Volume 106, Issue 3, pp. 514 - 523
BACKGROUND The objective of the current study was a retrospective evaluation of 100 consecutive premenopausal women with high‐risk, early breast carcinoma who... 
ovarian protection | adjuvant therapy | gonadotropin‐releasing hormone analogue | high‐risk early breast carcinoma | High-risk early breast carcinoma | Ovarian protection | Gonadotropin-releasing hormone analogue | Adjuvant therapy | AMENORRHEA | CYCLOPHOSPHAMIDE | TAMOXIFEN | METHOTREXATE | FLUOROURACIL | PREMENOPAUSAL PATIENTS | CANCER | gonadotropin-releasing hormone analogue | TRIAL | high-risk early breast carcinoma | THERAPY | ONCOLOGY | GOSERELIN | Cyclophosphamide - administration & dosage | Humans | Middle Aged | Estrogen Receptor Modulators | Gonadotropin-Releasing Hormone - analogs & derivatives | Fluorouracil - administration & dosage | Infertility, Female - chemically induced | Adult | Female | Ovary - drug effects | Gonadotropin-Releasing Hormone - therapeutic use | Retrospective Studies | Chemotherapy, Adjuvant | Carcinoma - pathology | Carcinoma - drug therapy | Premenopause | Ovary - physiology | Treatment Outcome | Breast Neoplasms - drug therapy | Pregnancy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Age of Onset | Infertility, Female - prevention & control | Methotrexate - administration & dosage | Pregnancy Outcome | Care and treatment | Gonadotropin releasing hormone | Patient outcomes | Physiological aspects | Breast cancer | Research | Ovaries
Journal Article
Journal Article
Journal Article
The Oncologist, ISSN 1083-7159, 11/2016, Volume 21, Issue 11, pp. 1298 - 1305
Background. Evidence on the management and treatment of male breast cancer is scant. We report the analysis of a multicenter Italian series of patients with... 
Eribulin | Treatment | Male breast cancer | Clinical practice | THERAPY | ONCOLOGY | CASE SERIES | Breast Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. 3021 - 3021
3021 Background: Even if patients with stage IV cancer (AC) may have prolonged remissions with chemotherapy (CT), the majority of them, will eventually... 
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2009, Volume 116, Issue 2, pp. 202 - 207
Abstract Objectives Vascular endothelial growth factor (VEGF), a mediator of tumor-associated immunodeficiency, plays a key role in angiogenesis and is a... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Maintenance immunotherapy | Interleukin-2 | Advanced ovarian cancer | 13 cis retinoic acid | BEVACIZUMAB | PLATINUM | RANDOMIZED-TRIAL | CHEMOTHERAPY | PACLITAXEL | OBSTETRICS & GYNECOLOGY | LIPOSOMAL DOXORUBICIN | THERAPY | ONCOLOGY | REGULATORY T-CELLS | 13-CIS RETINOIC ACID | Immunotherapy - methods | Follow-Up Studies | Interleukin-2 - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Isotretinoin - administration & dosage | T-Lymphocytes, Regulatory - immunology | Carboplatin - adverse effects | Neoplasm Recurrence, Local - immunology | Young Adult | Interleukin-2 - administration & dosage | Killer Cells, Natural - immunology | Adult | Female | Paclitaxel - administration & dosage | Neoplasm Recurrence, Local - blood | Ovarian Neoplasms - drug therapy | Taxoids - adverse effects | Vascular Endothelial Growth Factor A - blood | Carboplatin - administration & dosage | Ovarian Neoplasms - blood | Paclitaxel - adverse effects | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Isotretinoin - adverse effects | Ovarian Neoplasms - immunology | Care and treatment | Interleukins | Immunotherapy | Oncology, Experimental | Immunodeficiency | Research | Vascular endothelial growth factor | Cancer | Ovarian cancer
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 5/2007, Volume 56, Issue 5, pp. 699 - 708
Journal Article
Anticancer Research, ISSN 0250-7005, 01/2010, Volume 30, Issue 1, pp. 209 - 216
Background: Failure to eradicate all cancer stem cells, lymphocytopenia, and high levels of vascular endothelial growth factor (VEGF) may explain the limited... 
Cyclophosphamide | NK cells | 5-Fluorouracil | High-dose chemotherapy | VEGF | Carboplatin | Etoposide | IL-2 | Epirubicin | Methotrexate | Radiotherapy | Retinoic acid | STEM-CELL SUPPORT | ADJUVANT CHEMOTHERAPY | BONE-MARROW | epirubicin | methotrexate | RANDOMIZED-TRIAL | 13-CIS-RETINOIC ACID | PHASE-II | FOLLOW-UP | MAINTENANCE THERAPY | 5-fluorouracil | retinoic acid | ONCOLOGY | carboplatin | radiotherapy | cyclophosphamide | etoposide | high-dose chemotherapy | 13-CIS RETINOIC ACID | Cyclophosphamide - administration & dosage | Prospective Studies | Breast Neoplasms - immunology | Interleukin-2 - adverse effects | Humans | Middle Aged | Carcinoma, Ductal, Breast - immunology | Interleukin-2 - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Cyclophosphamide - adverse effects | Breast Neoplasms - therapy | CD4-CD8 Ratio | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Hematopoietic Stem Cell Transplantation - adverse effects | Killer Cells, Natural - immunology | Adult | Carcinoma, Ductal, Breast - pathology | Female | Treatment Outcome | Combined Modality Therapy | Carcinoma, Ductal, Breast - therapy | Tretinoin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Methotrexate - administration & dosage | Hematopoietic Stem Cell Transplantation - methods | Neoplasm Staging | Epirubicin - adverse effects
Journal Article
Cancer Medicine, ISSN 2045-7634, 08/2012, Volume 1, Issue 1, pp. 89 - 95
Journal Article